May 4, 2006 · In this article, the term “thrombotic thrombocytopenic purpura” is used to describe microangiopathic hemolytic anemia and thrombocytopenia occurring in adults without an …

Jan 9, 2019 · In this double-blind, controlled trial, we randomly assigned 145 patients with TTP to receive caplacizumab (10-mg intravenous loading bolus, followed by 10 mg daily …

May 1, 2024 · Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and …

May 25, 2017 · Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe …

Sep 12, 2024 · Two articles published jointly in the New England Journal of Medicine in 1991 began to define TTP more clearly and set the standard for the treatment of TTP that is still …

Jan 24, 2019 · Among patients with TTP, treatment with caplacizumab was associated with faster normalization of the platelet count; a lower incidence of a composite of TTP-related death, …

Oct 23, 2019 · Patients with hereditary TTP may appear to be healthy, but their increased risk of critical thrombosis is always present. This review describes the history, pathogenesis, …

Aug 11, 2014 · The management of thrombotic thrombocytopenic purpura (TTP) generally includes plasma exchange to raise ADAMTS13 levels and the use of immunosuppression …

Aug 13, 2014 · Thrombotic thrombocytopenic purpura (TTP) is due to genetic mutation or autoantibody against ADAMTS13, a von Willebrand factor–cleaving protease. The persistence …

Oct 23, 2019 · Hereditary thrombotic thrombocytopenic purpura (TTP), also known as Upshaw–Schulman syndrome, is a rare autosomal recessive disorder caused by ADAMTS13 …